SG11201810901VA - Compositions in the form of an injectable aqueous solution, comprising human glucagon and a statistical copolyamino acid - Google Patents
Compositions in the form of an injectable aqueous solution, comprising human glucagon and a statistical copolyamino acidInfo
- Publication number
- SG11201810901VA SG11201810901VA SG11201810901VA SG11201810901VA SG11201810901VA SG 11201810901V A SG11201810901V A SG 11201810901VA SG 11201810901V A SG11201810901V A SG 11201810901VA SG 11201810901V A SG11201810901V A SG 11201810901VA SG 11201810901V A SG11201810901V A SG 11201810901VA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- aqueous solution
- injectable aqueous
- human glucagon
- copolyamino acid
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 101500028775 Homo sapiens Glucagon Proteins 0.000 title abstract 3
- 239000002253 acid Substances 0.000 title abstract 3
- 239000007864 aqueous solution Substances 0.000 title abstract 3
- 150000007942 carboxylates Chemical class 0.000 abstract 1
- 239000003629 gastrointestinal hormone Substances 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1655221A FR3052071B1 (fr) | 2016-06-07 | 2016-06-07 | Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon et un co-polyaminoacide |
| FR1750221A FR3061660B1 (fr) | 2017-01-10 | 2017-01-10 | Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide |
| PCT/EP2017/063887 WO2017211917A1 (fr) | 2016-06-07 | 2017-06-07 | Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide statistique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810901VA true SG11201810901VA (en) | 2019-01-30 |
Family
ID=59021507
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810901VA SG11201810901VA (en) | 2016-06-07 | 2017-06-07 | Compositions in the form of an injectable aqueous solution, comprising human glucagon and a statistical copolyamino acid |
| SG11201810939PA SG11201810939PA (en) | 2016-06-07 | 2017-06-07 | Compositions in the form of an injectable aqueous solution, comprising human glucagon and an end-grafted copolyamino acid |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810939PA SG11201810939PA (en) | 2016-06-07 | 2017-06-07 | Compositions in the form of an injectable aqueous solution, comprising human glucagon and an end-grafted copolyamino acid |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10383918B2 (fr) |
| EP (2) | EP3463294B1 (fr) |
| JP (2) | JP2019517560A (fr) |
| KR (2) | KR20190026748A (fr) |
| CN (2) | CN109562063A (fr) |
| AU (2) | AU2017277590A1 (fr) |
| BR (2) | BR112018075250A2 (fr) |
| CA (2) | CA3026802A1 (fr) |
| MX (2) | MX2018015069A (fr) |
| SG (2) | SG11201810901VA (fr) |
| WO (2) | WO2017211918A1 (fr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3083089A1 (fr) * | 2018-06-29 | 2020-01-03 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes |
| CA3084688A1 (fr) | 2017-12-07 | 2019-06-13 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes |
| FR3083086A1 (fr) * | 2018-06-29 | 2020-01-03 | Adocia | Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide |
| MA51127A (fr) | 2017-12-07 | 2021-03-17 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes |
| WO2019110788A1 (fr) | 2017-12-07 | 2019-06-13 | Adocia | Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide |
| WO2019110838A1 (fr) * | 2017-12-07 | 2019-06-13 | Adocia | Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide |
| KR20240171195A (ko) * | 2017-12-07 | 2024-12-06 | 아도시아 | 인간 글루카곤 및 코-폴리아미노산을 포함하는 주사용 수용액 형태의 조성물 |
| FR3083087A1 (fr) * | 2018-06-29 | 2020-01-03 | Adocia | Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide |
| CN111683675A (zh) * | 2017-12-07 | 2020-09-18 | 阿道恰公司 | 包含人胰高血糖素和共聚氨基酸的呈可注射水溶液形式的组合物 |
| US20190275108A1 (en) * | 2017-12-07 | 2019-09-12 | Adocia | Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analogue and a co-polyamino acid |
| SG11202005319PA (en) | 2017-12-07 | 2020-07-29 | Adocia | Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid |
| WO2019110797A1 (fr) | 2017-12-07 | 2019-06-13 | Adocia | Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide |
| KR20200107951A (ko) | 2017-12-07 | 2020-09-16 | 아도시아 | 인간 글루카곤 및 코-폴리아미노산을 포함하는 주사용 수용액 형태의 조성물 |
| CN108174843B (zh) * | 2018-01-24 | 2018-11-13 | 广州市进德生物科技有限公司 | 一种胰高血糖素保护剂及其应用 |
| FR3084584B1 (fr) * | 2018-08-03 | 2020-11-06 | Adocia | Solution injectable a ph 7 comprenant du glucagon humain et un compose amphiphile porteur de radicaux hydrophobes |
| EP4091625A1 (fr) | 2021-05-22 | 2022-11-23 | Adocia | Compositions comprenant des hormones à brève durée d'action pour traiter ou prévenir l'obésité et pompes comprenant ladite composition |
| WO2022248419A2 (fr) | 2021-05-22 | 2022-12-01 | Adocia | Compositions comprenant des hormones à action courte pour le traitement ou la prévention de l'obésité et pompes comprenant ladite composition |
| EP4144362A1 (fr) | 2021-09-06 | 2023-03-08 | Adocia | Compositions comprenant des hormones à brève durée d'action pour traiter ou prévenir l'obésité et pompes comprenant ladite composition |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1202607A (en) * | 1968-01-10 | 1970-08-19 | Novo Terapeutisk Labor As | Improvements in or relating to stable glucagon solutions and their preparation |
| US6384016B1 (en) | 1998-03-13 | 2002-05-07 | Novo Nordisk A/S | Stabilized aqueous peptide solutions |
| FR2801226B1 (fr) | 1999-11-23 | 2002-01-25 | Flamel Tech Sa | Suspension colloidale de particules submicroniques de vectorisation de principes actifs et son mode de preparation |
| FR2840614B1 (fr) | 2002-06-07 | 2004-08-27 | Flamel Tech Sa | Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques |
| FR2881140B1 (fr) * | 2005-01-27 | 2007-04-06 | Flamel Technologies Sa | Copolyhydroxyalkylglutamines fonctionnalises par des groupements hydrophobes et leurs applications notamment therapeutiques |
| FR2902007B1 (fr) * | 2006-06-09 | 2012-01-13 | Flamel Tech Sa | Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s) ainsi que leurs applications notamment therapeutiques |
| FR2915683B1 (fr) * | 2007-05-03 | 2009-08-07 | Flamel Technologies Sa | Formulations pharmaceutiques auto-precipitantes pour la liberation modifiee de principe actif |
| US20110097386A1 (en) | 2009-10-22 | 2011-04-28 | Biodel, Inc. | Stabilized glucagon solutions |
| WO2011138802A1 (fr) | 2010-05-07 | 2011-11-10 | Sun Pharma Advanced Research Company Ltd., | Solution injectable |
| EP2635296B1 (fr) | 2010-11-03 | 2014-12-24 | Arecor Limited | Nouvelle composition contenant de glucagon |
| CN104159570A (zh) | 2011-12-29 | 2014-11-19 | 陈献 | 稳定的胰高血糖素纳米乳液 |
| WO2013104861A1 (fr) * | 2012-01-09 | 2013-07-18 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide substitue |
| WO2014096440A2 (fr) | 2012-12-21 | 2014-06-26 | Novozymes Biopharma Dk A/S | Composition |
| WO2015095389A1 (fr) | 2013-12-18 | 2015-06-25 | Aegis Therapeutics, Llc | Compositions pour administration de médicaments |
| US9334316B2 (en) | 2014-04-11 | 2016-05-10 | Oregon Health & Science University | Formulations comprising glucagon |
-
2017
- 2017-06-07 BR BR112018075250-9A patent/BR112018075250A2/pt not_active Application Discontinuation
- 2017-06-07 KR KR1020197000533A patent/KR20190026748A/ko not_active Withdrawn
- 2017-06-07 CN CN201780047755.9A patent/CN109562063A/zh active Pending
- 2017-06-07 SG SG11201810901VA patent/SG11201810901VA/en unknown
- 2017-06-07 SG SG11201810939PA patent/SG11201810939PA/en unknown
- 2017-06-07 JP JP2018564397A patent/JP2019517560A/ja active Pending
- 2017-06-07 CA CA3026802A patent/CA3026802A1/fr not_active Abandoned
- 2017-06-07 BR BR112018075259-2A patent/BR112018075259A2/pt not_active Application Discontinuation
- 2017-06-07 US US15/616,542 patent/US10383918B2/en not_active Expired - Fee Related
- 2017-06-07 JP JP2018564218A patent/JP2019521107A/ja active Pending
- 2017-06-07 AU AU2017277590A patent/AU2017277590A1/en not_active Abandoned
- 2017-06-07 KR KR1020197000540A patent/KR20190025905A/ko not_active Withdrawn
- 2017-06-07 MX MX2018015069A patent/MX2018015069A/es unknown
- 2017-06-07 WO PCT/EP2017/063888 patent/WO2017211918A1/fr not_active Ceased
- 2017-06-07 AU AU2017277589A patent/AU2017277589A1/en not_active Abandoned
- 2017-06-07 US US15/616,627 patent/US10485851B2/en not_active Expired - Fee Related
- 2017-06-07 CN CN201780049290.0A patent/CN109562064A/zh active Pending
- 2017-06-07 EP EP17728541.8A patent/EP3463294B1/fr not_active Not-in-force
- 2017-06-07 MX MX2018015070A patent/MX2018015070A/es unknown
- 2017-06-07 CA CA3027238A patent/CA3027238A1/fr not_active Abandoned
- 2017-06-07 WO PCT/EP2017/063887 patent/WO2017211917A1/fr not_active Ceased
- 2017-06-07 EP EP17728542.6A patent/EP3463295B1/fr not_active Not-in-force
Also Published As
| Publication number | Publication date |
|---|---|
| US20170348395A1 (en) | 2017-12-07 |
| JP2019521107A (ja) | 2019-07-25 |
| CA3027238A1 (fr) | 2017-12-14 |
| BR112018075259A2 (pt) | 2019-03-12 |
| KR20190025905A (ko) | 2019-03-12 |
| CN109562064A (zh) | 2019-04-02 |
| EP3463294B1 (fr) | 2020-08-05 |
| SG11201810939PA (en) | 2019-01-30 |
| KR20190026748A (ko) | 2019-03-13 |
| BR112018075250A2 (pt) | 2019-03-12 |
| US10383918B2 (en) | 2019-08-20 |
| WO2017211917A1 (fr) | 2017-12-14 |
| CA3026802A1 (fr) | 2017-12-14 |
| EP3463294A1 (fr) | 2019-04-10 |
| JP2019517560A (ja) | 2019-06-24 |
| EP3463295B1 (fr) | 2020-08-05 |
| AU2017277590A1 (en) | 2019-01-24 |
| CN109562063A (zh) | 2019-04-02 |
| EP3463295A1 (fr) | 2019-04-10 |
| MX2018015069A (es) | 2019-05-09 |
| MX2018015070A (es) | 2019-05-09 |
| US10485851B2 (en) | 2019-11-26 |
| AU2017277589A1 (en) | 2019-01-24 |
| US20170348394A1 (en) | 2017-12-07 |
| WO2017211918A1 (fr) | 2017-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810901VA (en) | Compositions in the form of an injectable aqueous solution, comprising human glucagon and a statistical copolyamino acid | |
| SA518400596B1 (ar) | محلول قابل للحقن عند الرقم الهيدروجيني 7 يشتمل على أنسولين قاعدي واحد على الأقل تتراوح نقطة (pi) التعادل الكهربائي الخاصة به من 5.8 إلى 8.5، و/أو أنسولين وجبات و/أو هرمون قناة هضمية، وحمض بولي أميني | |
| MX2025009746A (es) | Solucion inyectable a ph 7 que comprende al menos una insulina basal que tiene un pi de entre 5.8 y 8.5 y un copoliaminoacido con cargas de carboxilato y radicales hidrofobicos | |
| PH12020550828A1 (en) | Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid | |
| WO2019110797A8 (fr) | Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide | |
| PH12018502714A1 (en) | Nicotine particles and compositions | |
| PH12017501486A1 (en) | Nasal powder formulation for treatment of hypoglycemia | |
| MX2016005395A (es) | Formulacion estable de insulina glulisina. | |
| IL272141A (en) | Preparations in the form of an aqueous solution for injection containing at least human insulin A21G and suppressing glucagon activity with a meal | |
| MX2019005855A (es) | Formulaciones que se pueden pulverizar. | |
| PH12017502319A1 (en) | Injectable pharmaceutical formulations of lefamulin | |
| MX2025008231A (es) | Composiciones en forma de una solucion acuosa inyectable que comprende amilina, un receptor agonista de amilina o un analogo de amilina y un copoliaminoacido | |
| MX2016004328A (es) | Inmunopotenciador. | |
| SG11202005320VA (en) | Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid | |
| ZA201906037B (en) | Liquid composition containing pradofloxacin | |
| EA202091387A1 (ru) | Композиции в форме инъецируемого водного раствора, содержащие человеческий глюкагон и сополиаминокислоту | |
| MY187571A (en) | Krill oil preparations with optimal mineral and metal composition, low impurities and low and stable tma levels | |
| EP3777887A4 (fr) | Activateur d'action allergène comprenant de l'acide hyaluronique en tant que principe actif |